Pharmaceutical Market: An Overview
DOI:
https://doi.org/10.55927/ijis.v2i12.6272Keywords:
Pharmaceutical industry, Medications, HealthcareAbstract
Drug display has a substantial risk in terms of the investigation, occurrence, outcomes, and distribution of drugs generally. It is a dynamic and error-prone aspect of the healthcare production process. An overview of pharmaceuticals is provided in this abstract, with emphasis on their key traits, challenges, and methods.The pharmaceutical industry offers a vast array of brands, including generic drugs, biologics, vaccines, formula drugs, and investments in corporate cures. This is due to the ongoing advancements in science and biological research, as well as the growing demand for realistic scenarios in a range of medical contexts One of the trademarks of pharmaceutical presentations (R&D) is the allure of a significant reliance on testing. It takes a long time, money, and uncertainty to bring a new drug to market. It requires stringent preclinical and objective testing, supervisory permissions, and post-shopping follow-ups to ensure security and efficacy. Patents shield innovations and grant pharmaceutical companies a fenestella of uniqueness that helps them recover their large R&D expenses. However, this industry faces many challenges. Increasing healthcare costs, a rise in regulatory investigations, and pressure from payers and governments on prices have all contributed to a cost curb. In addition, there are still problems with research and development because of the rise in complicated diseases, antibiotic resistance, and the need for integrated healthcare. A shift toward biopharmaceuticals, digital healthcare, and precise therapies are just a few of the noteworthy themes that pharmaceutical advertising has helped to foster recently. The COVID-19 pandemic has increased the number of cure cases, revealing the manufacturing industry's susceptibility to pervasive health crises. Drug display is quite competitive, with minor biotech companies and two multinational alliances vying for market share. To expand device portfolios and gain access to new sciences, partnerships, acquisitions, and mergers are the most common approaches
Downloads
References
Aaker, D., and Joachimstaler, E., Brand Leadership, New York: Loose Press, 2000.28
Aaker, David A., dealing with logo fairness - Capitalising on the value of an emblem call, 1991, The loose Press, New York.
Blackett, T., Manufacturers and Branding, Interbrand, NY, 2004.
Blackett, T., brand medicine: Use and future capability of branding in pharmaceutical markets, International Magazine of Medical Marketing, 2001
Bhardwaj, Preshth, Indian Pharmaceutical marketplace: An outsourcing vacation spot, GITAM magazine of management, Vol. 3, No. 1, 2005, p. 114–127.
Buchholz, A., and Wordemann, W.: What makes prevailing brands unique? The hidden technique at the back of the arena’s most successful manufacturers John Wiley & Sons Ltd., England, 2000.
Cleland, Robin, Finskud, Lars and Raimondi, Vittorio, 9 prescriptions for Emblem Fitness, Market Chief, Spring 2004, p. 50–5.
Calfee, John E., The position of marketing in pharmaceutical studies and development, Pharmacoeconomic 2002; 20 Suppl., three: 77–85.
Chaganti, Subba Rao, Pharmaceutical advertising and marketing in India, GITAM Institute of Foreign Change, 1st edition, 2005, p. 39–46.
Calfee, op.cit., pg. 77-85
Calfee, op. cit., p. 77–85.
Chandler and Owen, op. cit.
Chandler, J., and Owen, M., developing manufacturers with qualitative studies, London: Sage, 2002.
Clifton, R., The future of brands: manufacturers and Branding, Inter brand, New York, 2004.
Country-wide health Council announcement: Direct-to-patron prescription drug advertising: evaluation and suggestions, Washington, DC, January 2002, http://www.national health council.org/ advocacy/DTC_paper.
Dr. Kumar, LakshmanY., brand fulfillment evaluation in decided on pharmaceutical therapeutic groups, IBRC Athens, 2005,
de Chematony, L. and DalFlmo Ri ley, F., professionals’ views about defining offerings brands and the concepts of services branding, the magazine of business research, Vol. forty-six, No. 2, 1999, p. 181–192
Elliott vs., New osteoporosis treatments provide diagnosis incentives: extra options to save you brittle bones and a couple of fractures vital for treatment, Am
Erickson, D., Branding goes international, The Commercial Enterprise and Medication Document, 2001, p. 60-71.
Frank Windmeijer, Eric de Laat, Rudy Douven, and Esther Mot, Pharmaceutical promoting and GP Prescription behavior, CPB dialogue Paper, CPB Netherlands Bureau for Monetary Coverage Evaluation, No. 30, 2004
Galambos L, The crucial and widely misunderstood role of marketing in
Pharmaceutical innovation dealt with at Rutgers College, 6 April 2001.
Galambos L, Sewell JE, Networks of innovation: vaccine improvement at Merck, Sharp & Dohme and Mulford, 1895–1995, Big Apple: Cambridge College Press, 1995.
Goniil F, Carter F, Petrova E, et al. Promoting of prescription drugs and its effect on physicians’ preference behavior, J Advertising 2002; 65(3):79–90.
IMS Global Insights, December 2006, www.imshealth.com
Kleinke JD, The fee of development: prescribed drugs within the health care marketplace, Health Affairs, 2001; 25(5); 43–60.
Kotler, P., advertising control, The Millennium edition, top Saddle River, Prentice Corridor, 2000, p. 255-258.
Kotler, op. cit., p. 255-258.
Kapferer, J. N., Strategic logo control, London: Kogan web page, 1997, p. 46.62.
Kshirsagar, Rajiv, The Indian Pharmaceutical industry: beyond 2005, express Pharma Pulse, 2003
Kapferer, J. N., Strategic logo management, The Loose Press, the Big Apple, 1991.
Kapferer, op.cit., pg. 46-62.
Med News 2002, April 1, http://www.ama-assn.org/sci-pubs/amnews/pick_02/ hlsb0401.htm.27
Moss, G. and Schuiling, I., A emblem logic for pharma: a probable approach based on FMCG enjoy International Journal of medical advertising, 2001.
Moss, G., Pharmaceutical brands: do they simply exist, Global Journal of
medical advertising, Vol. 2, trouble 1, 2001, pg. 23-33.
Nine. Peltzman, S., using prescription best....or from time to time, regulation 1987; 11 (3/4); 23-8.
Nordhaus WD, The health of countries: the contribution of stepped-forward health to residing standards, countrywide Bureau of financial studies (NBER), 2002; running paper no. w8818, http://www.nber.org/papers/w8818.
Ono, Yumiko, Prescription-drug makers heighten tough-promote processes, Wall Street magazine, August 1994.
Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic
medications: primary care, psychiatry, and different medical specialties, JAMA 1998; 279: 526-31.
Rodengen, J. L., The Legend of Pfizer, Write Stuff Syndicate, Inc., 2000.
Rosenthal MB, Bemdt ER, Donohue JM, et al. Merchandising of prescribed drugs to customers, N Engl. J Med 2002; 346: 498-505.
Schuiling and Moss, op. cit.
The destiny of Branding: learning from the demanding situations others have faced, Data monitor, may also 2006.
Weisz, Pam, Over-the-counter is going beneath the radar, Brandweek, June 1996,p. 39-42.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rehan Haider Rehan Haider
This work is licensed under a Creative Commons Attribution 4.0 International License.